2,6,16-Kauranetriol 2-O-beta-D-allopyranosideCAS# 195735-16-1 |
- Creticoside C
Catalog No.:BCN5707
CAS No.:53452-34-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 195735-16-1 | SDF | Download SDF |
PubChem ID | 91668402 | Appearance | Powder |
Formula | C26H44O8 | M.Wt | 484.6 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2R,3R,4R,5S,6R)-2-[[(1R,3R,4R,7R,9S,10R,13R,14R)-3,14-dihydroxy-5,5,9,14-tetramethyl-7-tetracyclo[11.2.1.01,10.04,9]hexadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
SMILES | CC1(CC(CC2(C1C(CC34C2CCC(C3)C(C4)(C)O)O)C)OC5C(C(C(C(O5)CO)O)O)O)C | ||
Standard InChIKey | RGKNTHMUHXNDHJ-GMOWVNSKSA-N | ||
Standard InChI | InChI=1S/C26H44O8/c1-23(2)8-14(33-22-20(31)19(30)18(29)16(11-27)34-22)9-24(3)17-6-5-13-7-26(17,12-25(13,4)32)10-15(28)21(23)24/h13-22,27-32H,5-12H2,1-4H3/t13-,14-,15-,16-,17+,18-,19-,20-,21-,22-,24+,25-,26-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside Dilution Calculator
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0636 mL | 10.3178 mL | 20.6356 mL | 41.2712 mL | 51.5889 mL |
5 mM | 0.4127 mL | 2.0636 mL | 4.1271 mL | 8.2542 mL | 10.3178 mL |
10 mM | 0.2064 mL | 1.0318 mL | 2.0636 mL | 4.1271 mL | 5.1589 mL |
50 mM | 0.0413 mL | 0.2064 mL | 0.4127 mL | 0.8254 mL | 1.0318 mL |
100 mM | 0.0206 mL | 0.1032 mL | 0.2064 mL | 0.4127 mL | 0.5159 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Atrasentan hydrochloride
Catalog No.:BCC1380
CAS No.:195733-43-8
- (+-)-Byakangelicin
Catalog No.:BCN5000
CAS No.:19573-01-4
- 2,16,19-Kauranetriol 2-O-beta-D-allopyranoside
Catalog No.:BCN1510
CAS No.:195723-38-7
- Methyl 4-O-feruloylquinate
Catalog No.:BCC9041
CAS No.:195723-10-5
- Piromidic Acid
Catalog No.:BCC3840
CAS No.:19562-30-2
- AP1903
Catalog No.:BCC5361
CAS No.:195514-63-7
- Chiirirhamnin
Catalog No.:BCN3179
CAS No.:195450-50-1
- Wortmannin
Catalog No.:BCC3874
CAS No.:19545-26-7
- Bay 11-7821(BAY 11-7082)
Catalog No.:BCC2244
CAS No.:19542-67-7
- JAK2 Inhibitor V, Z3
Catalog No.:BCC1667
CAS No.:195371-52-9
- Alphitolic acid
Catalog No.:BCN1189
CAS No.:19533-92-7
- Galantamine hydrobromide
Catalog No.:BCN2869
CAS No.:1953-04-4
- HTMT dimaleate
Catalog No.:BCC6736
CAS No.:195867-54-0
- (R)-Nepicastat HCl
Catalog No.:BCC4315
CAS No.:195881-94-8
- 25S-Inokosterone
Catalog No.:BCN3873
CAS No.:19595-18-7
- 17 alpha-propionate
Catalog No.:BCC1296
CAS No.:19608-29-8
- Angelol A
Catalog No.:BCN8036
CAS No.:19625-17-3
- Indole-3-acrylic acid methyl ester
Catalog No.:BCN1190
CAS No.:19626-92-7
- 4-Methoxycinnamaldehyde
Catalog No.:BCN2700
CAS No.:1963-36-6
- Bay 11-7085
Catalog No.:BCC5105
CAS No.:196309-76-9
- Axillarine
Catalog No.:BCN2059
CAS No.:19637-66-2
- Prosaptide TX14(A)
Catalog No.:BCC8020
CAS No.:196391-82-9
- Siegesmethyethericacid
Catalog No.:BCC9248
CAS No.:196399-16-3
- (4S,5R)-3-tert-butoxycarbony-2-(4-anisy)-4-phenyl-5-oxazolidinecarboxylic acid
Catalog No.:BCN8365
CAS No.:196404-55-4
Synthesis, Cytotoxic and Anti-proliferative Activity of Novel Thiophene, Thieno[2,3-b]pyridine and Pyran Derivatives Derived from 4,5,6,7-tetrahydrobenzo[b]thiophene Derivative.[Pubmed:28380235]
Acta Chim Slov. 2017 Mac;64(1):117-128.
Novel tetrahydrobenzo[b]thienopyrole derivatives are synthesized from 2-amino-3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophene (1) through its reaction with alpha-chloroacetone to give the corresponding N-alkyl derivative 3. Compound 3 undergoes ready cyclization in sodium ethoxide solution to give the tetrahydrobenzo[b]thienopyrrole 4. The latter compound 4 is used as the key starting material for the synthesis of thiophene, thieno[2,3-b]pyridine and pyran derivatives. The cytotoxicity of the synthesized products towards the human cancer cell lines namely gastric cancer (NUGC), colon cancer (DLD-1), liver cancer (HA22T and HEPG-2), breast cancer (MCF-7), nasopharyngeal carcinoma (HONE-1) and normal fibroblast (WI-38) cell lines are measured. Compounds 4, 7a, 7b, 8a, 8b, 10c, 10d, 10f, 12a, 12b, 14b and 15b exhibit the optimal cytotoxic effect against cancer cell lines. Compounds 7b and 14b show the maximum inhibitory effect and these are much higher than the reference CHS-828 (pyridyl cyanoguanidine). On the other hand, the anti-proliferative evaluations of these compounds with high potency against the cancer cell lines L1210, Molt4/C8, CEM, K562, K562/4 and HCT116 show that compounds 7b and 8b give IC50's against Molt4/C8 and CEM cell lines higher than that of the reference, doxorubicin.
Structural and Functional State of Erythrocyte Membranes in Mice at Different Stages of Experimental Parkinson's Disease Induced by Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP).[Pubmed:28382410]
Bull Exp Biol Med. 2017 Mar;162(5):597-601.
We studied some structural and functional parameters of erythrocyte membranes in mice at the late presymptomatic and early symptomatic stages of experimental Parkinson's disease induced by administration of MPTP (hemolysis, microviscosity of different regions of the lipid bilayer, LPO intensity, activity of antioxidant enzymes, and kinetic properties of acetylcholinesterase). At the presymptomatic stage, significant deviations of the studied parameters from the normal were observed; they were similar in direction and magnitude to those in humans with Parkinson's disease. At the early symptomatic stage, most parameters tended to normal. Microviscosity of bulk lipids increased at the presymptomatic stage and decreased after appearance of clinical symptoms. This dynamics probably reflects activation of compensatory mechanisms aimed at inhibition of oxidative stress triggered by the development of the pathological process.
Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIalpha dual inhibitors with DNA non-intercalative catalytic activity.[Pubmed:28384547]
Eur J Med Chem. 2017 Jun 16;133:69-84.
With the aim to develop novel antiproliferative agents, a new series of eighteen dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines were systematically designed, prepared, and investigated for their topoisomerase (topo) I and IIalpha inhibitory properties and antiproliferative effect in three different human cancer cell lines (HCT15, T47D, and HeLa). Compounds 22-30 which possess a meta- or para-phenol on 2-, or 6-position of central pyridine ring showed significant dual topo I and topo IIalpha inhibitory activities with strong antiproliferative activities against all the tested human cancer cell lines. However, compounds 13-21 which possess an ortho-phenol on 2-, or 6-position of central pyridine ring did not show significant topo I and topo IIalpha inhibitory activities but displayed moderate antiproliferative activities against all the tested human cancer cell lines. Compound 23 exhibited the highest antiproliferative potency as much as 348.5 and 105 times compared to etoposide and camptothecin, respectively, in T47D cancer cell line. The structure-activity relationship study revealed that the para position of a hydroxyl group at 2-and 6-phenyl ring and chlorine atom at the para position of 4-phenyl ring of the central pyridine exhibited the most significant topo I and topo IIalpha inhibition, which might indicate introduction of the chlorine atom at the phenyl ring of 4-pyridine have an important role as dual inhibitors of topo I and topo IIalpha. Compound 30 which showed the most potent dual topo I and topo IIalpha inhibition with strong antiproliferative activity in T47D cell line was selected to perform further study on the mechanism of action, which revealed that compound 30 functions as a potent DNA non-intercalative catalytic topo I and IIalpha dual inhibitor.
A Novel Methodology for Synthesis of 1,5,6-Trisubstituted 2(1H)-Pyrazinones of Biological Interest.[Pubmed:28381677]
Chem Pharm Bull (Tokyo). 2017;65(4):365-372.
In this report, we describe a new method for the synthesis of densely functionalized 2(1H)-pyrazinones. Treatment of mesoionic 1,3-oxazolium-5-olates with carbanions derived from activated methylene isocyanides (p-toluenesulfonylmethyl isocyanide (TosMIC) and ethyl isocyanoacetate) causes a novel ring transformation affording 2(1H)-pyrazinones in moderate to high yields. The cytotoxicity and antibacterial activity of some of the obtained products were studied and some of the products exhibited tumor-specific cytotoxicity.